Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease

Publisher： Bentham Science Publishers

E-ISSN： 2212-2710|3|1|1-16

ISSN： 1872-213X

Source： Recent Patents on Inflammation & Allergy Drug Discovery, Vol.3, Iss.1, 2009-01, pp. : 1-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Signaling Pathways Associated with Inflammatory Bowel Disease

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 4, Iss. 2, 2010-06 ,pp. : 105-117

Bentham Science Publishers

Access to resources Recommend Favorite

Rifaximin - Chitosan Nanoparticles for Inflammatory Bowel Disease (IBD)

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 11, Iss. 1, 2017-08 ,pp. : 41-52

Bentham Science Publishers

Access to resources Recommend Favorite

Vcsa1 Gene Peptides for the Treatment of Inflammatory and Allergic Reactions

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 1, Iss. 2, 2007-06 ,pp. : 124-132

Bentham Science Publishers

Access to resources Recommend Favorite

The Monocyte Locomotion Inhibitory Factor an Anti-Inflammatory Peptide; Therapeutics Originating from Amebic Abscess of the Liver

By  

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 5, Iss. 1, 2011-01 ,pp. : 7-12

Bentham Science Publishers

Access to resources Recommend Favorite

The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease

By  

Recent Patents on Drug Delivery & Formulation, Vol. 8, Iss. 1, 2014-04 ,pp. : 3-11

Bentham Science Publishers

Access to resources Recommend Favorite